Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

Financial Data and Key Metrics Changes - Third quarter revenue was $339 million, bringing year-to-date revenue to $988 million, with reported revenue reflecting a $153 million impact from last year's portfolio transitions [4][10] - Adjusted earnings per share increased 10% in the quarter to $1.31 and 11% year-to-date to $3.67, indicating strong earnings quality and durability [5][14] - Adjusted gross margin was 60.2% in the third quarter, up 250 basis points year-over-year, driven by the adoption of NexSys technology and divestiture of the Whole Blood business [11][12] - Free cash flow for the third quarter was $74 million, with year-to-date free cash flow reaching $165 million, representing a threefold increase compared to the prior year [15][16] Business Line Data and Key Metrics Changes - Hospital revenue was $144 million in the third quarter, down 1% but up 2% year-to-date organically, with blood management technologies growing 8% in the quarter [5][6] - Plasma revenue was $139 million, up 3% on a reported basis, with organic growth of 20% in the quarter, driven by share gains and collection volume [8][9] - Blood Center revenue was $57 million in the quarter, growing 3% organically, primarily due to international plasma demand [9][10] Market Data and Key Metrics Changes - U.S. plasma collections grew in the low double digits in the third quarter, with the company holding approximately 50% global market share [8][9] - The hospital business is expected to deliver reported and organic growth of approximately 4% at the low end of the prior 4%-7% range [7][10] Company Strategy and Development Direction - The company is focused on returning the Interventional Technologies franchise to sustainable growth in fiscal 2027, with targeted actions underway to strengthen this segment [18][19] - The Vivisure acquisition is expected to enhance the company's leadership in vascular closure, with a market opportunity estimated at $300 million [44][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the plasma business, highlighting strong relationships and a favorable market environment [24][26] - The company anticipates continued margin expansion and strong cash flow generation, with a focus on disciplined capital deployment [15][21] Other Important Information - Adjusted operating income increased 4% year-to-date to $254 million, with adjusted operating margin expanding 200 basis points to 25.7% [13][14] - The company raised its full-year revenue guidance to a decline of 1%-3%, reflecting improved performance across Plasma, Blood Center, and Blood Management Technologies [10][11] Q&A Session Summary Question: Can you provide insights on plasma collections and market growth? - Management indicated that share gains and collection volume are driving growth, with double-digit increases in both U.S. and international collections [24][25] Question: What are the expectations for margins moving forward? - Management expects smaller increments in margin improvements in the future, with ongoing focus on operational efficiency [29][30] Question: What is the status of the IVT business and competition? - Management noted that 70% of the decline in IVT was due to specific market disruptions, but they are confident in returning to growth with the right strategies in place [35][36] Question: Can you elaborate on the Vivisure acquisition and its market potential? - The acquisition is seen as a significant opportunity to enhance the company's position in vascular closure, with a focus on a stepwise approach to market entry [44][47] Question: How is the company addressing the challenges in the hospital business? - Management highlighted strong performance in blood management technologies and a focus on stabilizing the IVT segment as key to future growth [81][82]

Haemonetics (NYSE:HAE) FY Conference Summary Company Overview - Haemonetics is a global leader in plasma apheresis with a $1 billion addressable market growing at mid-single digits, providing durable EBITDA and attractive returns on invested capital [2][3] - The company is diversifying into MedSurg markets to reduce volatility and systemic risk associated with its core plasma business [3] Financial Performance - The company has achieved an 8% total revenue compound annual growth rate and a 13% organic revenue growth rate, excluding a major customer transition [5] - Operating income margin improved by 770 basis points, reaching 26.3% in the first half of the fiscal year [6][28] - Adjusted EPS is expected to compound at approximately 17% [6] - Free cash flow has more than doubled, reflecting the strength and optionality of the business [21] Strategic Initiatives - The company has focused on building high-quality, sustainable growth engines, emphasizing revenue, margin, and cash flow expansion [4] - A significant shift in revenue sources has occurred, with high-growth, high-margin businesses now representing 85% of total revenue, up from 30% in FY22 [6] - Haemonetics has exited or de-emphasized non-core assets to focus on scalable, therapeutically agnostic technologies [7] Core Product Platforms 1. **Plasma Apheresis** - The foundational earnings engine with over 50% market share in a $1 billion global market [8] - Strong end-market demand supported by a $30 billion global biopharmaceutical industry [8] - The company has a competitive advantage through superior technology and a bi-directionally integrated plasma collection platform [9][10] 2. **TEG (Viscoelastic Testing)** - The second-largest growth driver with a $400 million addressable market, growing in mid-single digits [11][12] - TEG has a 45% market share and is positioned to capture additional market opportunities through new product launches [12] 3. **Vascular Closure Technologies** - Represents a $2.5 billion total market opportunity, with a focus on electrophysiology [15] - The recent acquisition of Vivasure is expected to enhance the company's position in large bore closure markets, estimated at $300 million [18][30] Market Dynamics - The plasma business is experiencing a "trifecta" of growth through share gains, pricing premiums, and normalization of collections [40] - The company is well-positioned for continued growth, with no single customer representing more than 10% of total revenue [39] Capital Allocation Strategy - The company has deployed $1.3 billion in capital over four years, focusing on organic growth, M&A, and shareholder returns [22] - Priorities include organic investments, M&A (paused for now), and share buybacks, with $225 million returned to shareholders in the past year [44][45] Future Outlook - The company anticipates continued margin expansion and operational improvements, with a focus on leveraging its core platforms for growth [26][27] - The upcoming fiscal year (FY27) is expected to see normalized growth in plasma and further advancements in the MedSurg business [24][25] Conclusion - Haemonetics is positioned for sustainable growth through strategic diversification, strong financial performance, and a focus on core product platforms, with a clear roadmap for future value creation [20][23]